Results 21 to 30 of about 66,822 (310)

Medication‐related osteonecrosis of the jaw leading to sepsis in a patient with rheumatoid arthritis: A case report and clinical implications

Clinical Case Reports, 2023
Key Clinical Message Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a ...
Kazuhiko Iwasaki, Akihito Okazaki
doaj   +1 more source

Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid

Antibiotics, 2021
The use of local antibiotics to treat bone infections has been questioned due to a lack of clinical efficacy and emerging information about Staphylococcus aureus colonization of the osteocyte-lacuno canalicular network (OLCN).
Emmanuela Adjei-Sowah, Yue Peng, Jason Weeks, Jennifer H. Jonason, Karen L. de Mesy Bentley, Elysia Masters, Yugo Morita, Gowrishankar Muthukrishnan, Philip Cherian, X. Eric Hu, Charles E. McKenna, Frank H. Ebetino, Shuting Sun, Edward M. Schwarz, Chao Xie   +14 more
doaj   +1 more source

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

Frontiers in Endocrinology, 2021
ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment.
Yasuaki Hirooka, Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +7 more
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

Effect of bisphosphonate on temporomandibular joint in osteopenia-induced rats by botulinum toxin A injection on masticatory muscle: a preliminary study

Maxillofacial Plastic and Reconstructive Surgery, 2019
Background Botulinum toxin injection on the masticatory muscle induces the osteopenic condition on the ipsilateral condyle. Bisphosphonate suppresses bone resorption and is used to treat osteopenic or osteoporotic condition.
Jae-Young Kim, Dae-Hoon Kim, Hyo-Won Jang, Kwang-Ho Park, Jong-Ki Huh   +4 more
doaj   +1 more source

Prevention of osteoporotic refractures in regional Australia [PDF]

, 2017
Objective: Clinical guidelines recommend that patients who sustain a minimal trauma fracture (MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) therapy if diagnosed with osteoporosis.
Davidson, E, Doyle, Z, Fielding, K, McGirr, J, Seal, A   +4 more
core   +2 more sources

Mechanism of bisphosphonate-related osteonecrosis of the jaw (BRONJ) revealed by targeted removal of legacy bisphosphonate from jawbone using competing inert hydroxymethylene diphosphonate

eLife, 2022
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is rare, BRONJ has caused apprehension among patients and healthcare providers and
Hiroko Okawa, Takeru Kondo, Akishige Hokugo, Philip Cherian, Jesus J Campagna, Nicholas A Lentini, Eric C Sung, Samantha Chiang, Yi-Ling Lin, Frank H Ebetino, Varghese John, Shuting Sun, Charles E McKenna, Ichiro Nishimura   +13 more
doaj   +1 more source

Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial [PDF]

, 2018
Background Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders in horses, data regarding
Gillett, Ashley N., McNulty, Margaret A., Mitchell, Colin F., Richbourg, Heather A.   +3 more
core   +1 more source

Bisphosphonate conjugation for bone specific drug targeting

Bone Reports, 2018
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone ...
Kristen B. Farrell, Alexander Karpeisky, Douglas H. Thamm, Shawn Zinnen   +3 more
doaj   +1 more source

Etidronate as A Weak Chelating Agent on Root Canal Dentin: An Update Review [PDF]

Journal of Clinical and Diagnostic Research, 2017
Successful root canal treatment depends on proper biomechanical cleaning and shaping of root canal system followed by threedimensional obturation. Irrigation solutions and chelating agents are used during root canal treatment to assist in smear layer ...
Samah Samir Bedir, Hossam Mossa, Ahmed Mohammed Hassan   +2 more
doaj   +1 more source